Results 21 to 30 of about 1,089,428 (267)
Stem Cells International, 2022 Cellular therapies, deemed live medicine, have brought a wave of new generation biological therapies to treat previously untreatable diseases such as cancers and degenerative diseases like osteoarthritis.
Kiran Shah +6 more
doaj +1 more source
Current Oncology, 2022 Background: The Canadian Blood Services Cord Blood Bank (CBS CBB) was created to improve access to stem cell products for transplantation for patients across ethnic groups.
Gaganvir Parmar +9 more
doaj +1 more source
Stem-cell ecology and stem cells in motion
Blood, 2008 Abstract This review highlights major scientific developments over the past 50 years or so in concepts related to stem-cell ecology and to stem cells in motion. Many thorough and eloquent reviews have been presented in the last 5 years updating progress in these issues.
Thalia, Papayannopoulou +1 more
openaire +3 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Objectives The association between exposure to dinutuximab beta (DB) and event‐free survival (EFS) or overall survival (OS) of neuroblastoma patients was assessed using data collected during three clinical trials (five cohorts). Methods A systematic review (March 2026) was conducted to identify relevant studies (prospective; registered DB ...
Przemysław Holko +19 more
wiley +1 more source
Dokuz Eylül Üniversitesi Tıp Fakültesi Dergisi, 2019 A stem cell is an undifferentiated cell that can self-renew itself and can commit to a specific cell type. Depending on their residency, stem cells are classified into two main categories as embryonic stem cells and adult stem cells. According to their differentiation and developmental potential, stem cells may be classified as totipotent, pluripotent,
openaire +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Results of COG ANBL1221 changed treatment paradigms for patients with relapsed/refractory neuroblastoma. Chemoimmunotherapy with irinotecan/temozolomide/dinutuximab is now used as both bridge therapy following suboptimal response to induction and as treatment in first relapse.
Elizabeth Sokol +6 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Medication nonadherence during the first 100 days after pediatric hematopoietic stem cell transplantation (HSCT) and during oncology treatment increases risk for complications. BMT4me is a caregiver‐facing mobile health (mHealth) application providing medication reminders, symptom tracking, and note‐taking features to support ...
Micah A. Skeens +4 more
wiley +1 more source
Interleukin 21 Receptor Affects Adipogenesis of Human Adipose-Derived Stem/Stromal Cells
Stem Cells International, 2022 Dysfunctions in adipose tissue cells are responsible for several obesity-related metabolic diseases. Understanding the process of adipocyte formation is thus fundamental for understanding these diseases.
Bruna Cristina Falavinha +7 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Survival after relapse in pediatric acute myeloid leukemia (AML) remains poor, highlighting the critical importance of identifying prognostic factors to guide optimal relapse management. Methods We investigated the prognostic impact of multiparameter flow cytometry (MFC) measurable residual disease (MRD) in 188 patients with first ...
Camilla Poulsen +21 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose Despite 5‐year survival rates of over 90% among children and adolescents/young adults (CAYAs) with classic Hodgkin lymphoma (cHL), 15%–20% relapse after frontline therapy. Prior analysis of frontline Children's Oncology Group (COG) clinical trials demonstrated that, despite similar rates of relapse, non‐Hispanic Black (NHB) and ...
Mallorie B. Heneghan +14 more
wiley +1 more source